Inhibrx
INBX
88 hedge funds and large institutions have $149M invested in Inhibrx in 2025 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 22 increasing their positions, 34 reducing their positions, and 14 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1% less capital invested
Capital invested by funds: $151M → $149M (-$2.03M)
2.43% less ownership
Funds ownership: 74.52% → 72.09% (-2.4%)
4% less funds holding
Funds holding: 92 → 88 (-4)
29% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 14
35% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 34
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$3.94M |
| 2 |
State Street
Boston,
Massachusetts
|
+$414K |
| 3 |
RAM
Readystate Asset Management
Chicago,
Illinois
|
+$347K |
| 4 |
Franklin Resources
San Mateo,
California
|
+$287K |
| 5 |
Millennium Management
New York
|
+$264K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$2.52M |
| 2 |
BlackRock
New York
|
-$1.34M |
| 3 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$1.34M |
| 4 |
SC
Slotnik Capital
Dallas,
Texas
|
-$1.33M |
| 5 |
PA
Perceptive Advisors
New York
|
-$1.11M |
INBX Hedge Fund Activity: Q2 2025 in Review
88 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Inhibrx (INBX) for Q2 2025, worth a combined $149M — down 1.3% from $151M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of INBX and 10 opened new positions — a net loss of 4 holders — while 34 trimmed existing stakes and 22 added.
The largest buyer was Woodline Partners, adding an estimated $3.94M. The largest seller was PFM Health Sciences, cutting an estimated $2.52M.
- 88 institutional investors held Inhibrx (INBX) as of Q2 2025, down from 92 in Q1 2025.
- Funds reported $149M of Inhibrx stock for Q2 2025, down 1.3% quarter-over-quarter.
- 10 funds opened new Inhibrx positions in Q2 2025 and 14 closed out, a net change of -4 holders.
- The largest Inhibrx buyer in Q2 2025 was Woodline Partners, an estimated $3.94M added.
- The largest Inhibrx seller in Q2 2025 was PFM Health Sciences, an estimated $2.52M sold.
Based on aggregated 13F filings for Q2 2025.